Japanese company Takeda Pharmaceutical Company is all set to collaborate with NuBiyota to develop microbial ecosystem therapeutic products for gastroenterology (GI) indications.

Under the partnership, NuBiyota’s microbiome platform for GI indications will be used to advance oral microbial consortia products.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition to receiving an upfront payment, NuBiyota is eligible for success-based development, regulatory and commercial milestones and tiered royalties based on net sales of the products.

Takeda Pharmaceutical Company gastroenterology therapeutic area unit head Asit Parikh said: “We are excited to partner with NuBiyota as this collaboration reinforces Takeda’s long-term commitment to unmet medical need in gastroenterology and adds to our other microbiome-related partnerships.

"Through these partnerships, we are exploring both microbial consortia and microbiome derived bioactives to investigate how the microbiome can be harnessed for treatment of GI diseases."

“Through these partnerships, we are exploring both microbial consortia and microbiome derived bioactives to investigate how the microbiome can be harnessed for treatment of GI diseases.”

See Also:

NuBiyota clinic-ready, microbial consortia, microbial ecosystem therapeutic offers an entry point for clinical evaluation of microbiome based therapeutics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These products will help improve understanding of the role of microbiota in GI disease.

Through specialised and strategic in-house development, external partnerships, in-licensing and acquisitions, Takeda has various early stage GI assets currently in development.

The company focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas with vaccines.